Intra-Cellular Therapies Stock Forecast, Price & News

+0.16 (+0.37 %)
(As of 06/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume290,624 shs
Average Volume559,897 shs
Market Capitalization$3.50 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ITCI News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

Intra-Cellular Therapies logo

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson's disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.28 out of 5 stars

Medical Sector

897th out of 2,100 stocks

Pharmaceutical Preparations Industry

436th out of 831 stocks

Analyst Opinion: 1.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Intra-Cellular Therapies (NASDAQ:ITCI) Frequently Asked Questions

Is Intra-Cellular Therapies a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Intra-Cellular Therapies stock.
View analyst ratings for Intra-Cellular Therapies
or view top-rated stocks.

What stocks does MarketBeat like better than Intra-Cellular Therapies?

Wall Street analysts have given Intra-Cellular Therapies a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Intra-Cellular Therapies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Intra-Cellular Therapies' next earnings date?

Intra-Cellular Therapies is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Intra-Cellular Therapies

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) released its quarterly earnings results on Sunday, May, 9th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.81) by $0.16. The biopharmaceutical company earned $15.88 million during the quarter, compared to analyst estimates of $15.74 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 39.41% and a negative net margin of 617.78%.
View Intra-Cellular Therapies' earnings history

How has Intra-Cellular Therapies' stock been impacted by COVID-19 (Coronavirus)?

Intra-Cellular Therapies' stock was trading at $17.77 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ITCI stock has increased by 142.9% and is now trading at $43.16.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ITCI?

7 equities research analysts have issued 1-year price targets for Intra-Cellular Therapies' stock. Their forecasts range from $36.00 to $70.00. On average, they anticipate Intra-Cellular Therapies' share price to reach $47.43 in the next twelve months. This suggests a possible upside of 9.9% from the stock's current price.
View analysts' price targets for Intra-Cellular Therapies
or view top-rated stocks among Wall Street analysts.

Who are Intra-Cellular Therapies' key executives?

Intra-Cellular Therapies' management team includes the following people:
  • Dr. Sharon Mates, Co-Founder, Chairman, CEO & Pres (Age 68, Pay $1.48M)
  • Mr. Lawrence J. Hineline CPA, CPA, Sr. VP of Fin., CFO, Treasurer & Assistant Sec. (Age 65, Pay $706.21k)
  • Mr. Michael I. Halstead J.D., Exec. VP, Gen. Counsel & Sec. (Age 48, Pay $849.93k)
  • Dr. Suresh K. Durgam M.D., Sr. VP & Chief Medical Officer (Age 52, Pay $730.36k)
  • Mr. Mark Neumann, EVP & Chief Commercial Officer (Age 58, Pay $973.3k)
  • Dr. Robert E. Davis, Sr. VP & Chief Scientific Officer (Age 70)
  • Mr. Juan Fernando Sanchez, VP of Corp. Communications & Investor Relations (Age 50)
  • Ms. Karen Patruno Sheehy Esq., Sr. VP & Chief Compliance Officer (Age 59)
  • Dr. Michael Olchaskey, Sr. VP & Head of Regulatory Affairs
  • Mr. John A. Bardi, Sr. VP of Market Access, Policy & Gov. Affairs

Who are some of Intra-Cellular Therapies' key competitors?

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Who are Intra-Cellular Therapies' major shareholders?

Intra-Cellular Therapies' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Wasatch Advisors Inc. (8.04%), BlackRock Inc. (7.58%), Lord Abbett & CO. LLC (2.61%), Samlyn Capital LLC (1.69%), Schroder Investment Management Group (1.63%) and TimesSquare Capital Management LLC (1.51%). Company insiders that own Intra-Cellular Therapies stock include Andrew Satlin, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Mark Neumann, Michael Halstead, Sharon Mates and Suresh K Durgam.
View institutional ownership trends for Intra-Cellular Therapies

Which major investors are selling Intra-Cellular Therapies stock?

ITCI stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Dimensional Fund Advisors LP, Samlyn Capital LLC, Clearbridge Investments LLC, Tekla Capital Management LLC, Northern Trust Corp, SG Americas Securities LLC, and JPMorgan Chase & Co.. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Mark Neumann, Michael Halstead, Sharon Mates, and Suresh K Durgam.
View insider buying and selling activity for Intra-Cellular Therapies
or view top insider-selling stocks.

Which major investors are buying Intra-Cellular Therapies stock?

ITCI stock was acquired by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Franklin Resources Inc., TimesSquare Capital Management LLC, BlackRock Inc., Goldman Sachs Group Inc., Wasatch Advisors Inc., Nicholas Investment Partners LP, and Suvretta Capital Management LLC.
View insider buying and selling activity for Intra-Cellular Therapies
or or view top insider-buying stocks.

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intra-Cellular Therapies' stock price today?

One share of ITCI stock can currently be purchased for approximately $43.16.

How much money does Intra-Cellular Therapies make?

Intra-Cellular Therapies has a market capitalization of $3.50 billion and generates $22.81 million in revenue each year. The biopharmaceutical company earns $-227,010,000.00 in net income (profit) each year or ($3.23) on an earnings per share basis.

How many employees does Intra-Cellular Therapies have?

Intra-Cellular Therapies employs 383 workers across the globe.

What is Intra-Cellular Therapies' official website?

The official website for Intra-Cellular Therapies is

Where are Intra-Cellular Therapies' headquarters?

Intra-Cellular Therapies is headquartered at 430 EAST 29TH STREET, NEW YORK NY, 10016.

How can I contact Intra-Cellular Therapies?

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]

This page was last updated on 6/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.